原始出處紀錄
決策級主要結果 (Topline)
Connect Biopharma 公布 rademikibart 治療異位性皮膚炎的第三期初步結果
此 8-K 揭露合作夥伴 Simcere 在中國進行之 rademikibart 治療中重度異位性皮膚炎第三期 52 週試驗的初步結果。另亦公布一項第一期靜脈注射藥理學試驗的初步結果。這些資料發布構成監管／臨床里程碑事件。
關鍵事實
來源摘錄
cntb-20260329 0001835268 false 0001835268 2026-03-29 2026-03-30 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________ FORM 8-K ________________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 29, 2026 ________________________________________ Connect Biopharma Holdings Limited (Exact name of Registrant as Specified in Its Charter) ________________________________________ Cayman Islands 001-40212 Not Applicable (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 3580 Carmel Mountain Road , Suite 200 San Diego , California 92130 (Address of Principal Executive O